Breast cancer remains a leading cause of cancer-related mortality globally, underscoring the critical need for early detection to improve survival rates and reduce treatment invasiveness. This review synthesizes advancements in imaging technologies that enhance early diagnosis, focusing on their clinical applications, limitations, and future potential.
Introduction
Breast cancer accounts for 25% of cancer cases in women, with survival rates significantly higher in developed nations due to advanced screening programs. Traditional methods like clinical exams and mammography have been cornerstone tools, yet emerging technologies now complement these approaches, particularly for high-risk populations and dense breast tissue.
Mammography: Evolution and Innovations
Mammography remains the gold standard for screening, detecting 75% of cancers before palpability. Transitioning from analog to digital systems has improved sensitivity, reduced radiation doses by 30–50%, and enabled advanced processing techniques. Key advancements include:
Tomosynthesis (3D Mammography): Reduces tissue overlap artifacts, increasing cancer detection by 30–40% and lowering recall rates. Synthesized 2D images minimize radiation exposure while maintaining diagnostic accuracy.
Contrast-Enhanced Spectral Mammography (CESM): Combines iodine contrast with mammography to highlight tumor vascularization, offering MRI-like accuracy for invasive lobular carcinomas and occult lesions.
BI-RADS Classification: Standardizes reporting and risk stratification, though variability in categories like BI-RADS 3 and 4 necessitates supplementary imaging or biopsy.
Ultrasound: Complementing Mammography
Breast ultrasound excels in differentiating solid masses from cysts and is indispensable for dense breasts. Innovations include:
Automated 3D Ultrasound: Enhances reproducibility and detects mammographically occult cancers.
Contrast-Enhanced Ultrasound (CEUS): Uses microbubbles to assess vascular patterns, aiding in lesion characterization and reducing unnecessary biopsies.
Magnetic Resonance Imaging (MRI)
MRI boasts 94% sensitivity, particularly for high-risk patients (e.g., BRCA carriers) and dense breasts. It excels in preoperative staging, monitoring neoadjuvant therapy response, and evaluating implants. Limitations include high cost, gadolinium use, and false positives. Recent 3-Tesla systems improve spatial resolution, while abbreviated protocols reduce scan time without compromising accuracy.
Emerging Modalities
Thermography: Measures heat patterns via infrared or liquid crystal plates. Dynamic Angiothermography (DATG) identifies angiogenesis-linked thermal changes but lacks size assessment and requires validation.
Molecular Breast Imaging (MBI): Utilizes radioactive tracers for dense breasts, showing promise in detecting small tumors, though limited by availability and cost.
PET/CT: Primarily used for metastatic staging, with limited resolution for early detection.
Discussion: Screening Guidelines and Comparative Analysis
Screening protocols vary by risk profile:
Average Risk: Biennial mammography starting at 40–50 years.
High Risk: Annual MRI + mammography from age 30, particularly for BRCA carriers.
Dense Breasts: Supplemental ultrasound or tomosynthesis.
A comparison matrix (Table 4) highlights strengths and weaknesses:
Mammography: High screening utility but limited sensitivity in dense tissue.
MRI: Superior sensitivity but high cost and false positives.
Ultrasound: Radiation-free but operator-dependent.
Challenges and Future Directions
Current gaps include accessibility, radiation risks, and overdiagnosis. Promising advancements include:
AI Integration: Enhances diagnostic accuracy and reduces radiologist workload.
Noninvasive Biomarkers: Liquid biopsies combined with imaging for precision screening.
Hybrid Techniques: PET-MRI and optoacoustic imaging for comprehensive assessment.
Conclusion
Early detection through advanced imaging significantly improves breast cancer outcomes. While mammography remains foundational, integrating ultrasound, MRI, and emerging technologies tailors screening to individual risk. Future innovations must prioritize affordability, reduced radiation, and personalized protocols to bridge global disparities in breast cancer care. Regular screenings and multidisciplinary collaboration remain pivotal in combating this disease.
Full text
https://www.xiahepublishing.com/2835-3315/CSP-2024-00032
The study was recently published in the Cancer Screening and Prevention .
Cancer Screening and Prevention (CSP) publishes high-quality research and review articles related to cancer screening and prevention. It aims to provide a platform for studies that develop innovative and creative strategies and precise models for screening, early detection, and prevention of various cancers. Studies on the integration of precision cancer prevention multiomics where cancer screening, early detection and prevention regimens can precisely reflect the risk of cancer from dissected genomic and environmental parameters are particularly welcome.
